Trial Profile
Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary)
- Indications Brain cancer; CNS cancer
- Focus Adverse reactions; Pharmacokinetics
- 18 Mar 2019 Status changed from recruiting to discontinued.
- 03 Apr 2017 Planned number of patients changed from 40 to 55.
- 03 Apr 2017 Planned primary completion date changed from 1 Jan 2017 to 31 Dec 2018.